{"eventGroups":[{"deathsNumAffected":3,"deathsNumAtRisk":26,"description":"BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.","id":"EG000","otherNumAffected":7,"otherNumAtRisk":26,"seriousNumAffected":7,"seriousNumAtRisk":26,"title":"Bexarotene + GM-CSF"}],"frequencyThreshold":"5","otherEvents":[{"organSystem":"Hepatobiliary disorders","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":26}],"term":"Elevated ALT"},{"organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26}],"term":"Hypertriglyceridemia"},{"organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26}],"term":"Muscle weakness"}],"seriousEvents":[{"organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26}],"term":"Neutropenic infection"},{"organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":26}],"term":"Dyspnea"},{"organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26}],"term":"Atrial flutter"},{"organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":26}],"term":"acute subdural hemmorrhage"},{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":26}],"term":"sepsis"}]}